Business
BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development
VANCOUVER, BC / ACCESS Newswire / September 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce the successful completion of proof-of-concept trials for its Semaglutide oral dissolvable ...
About this update from Bionxt Solutions Inc
[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / September 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce the successful completion of proof-of-concept trials for its Semaglutide oral dissolvable film ("ODF") program at Vektor Pharma TF GmbH ("Vektor Pharma"), the Company's wholly owned German subsidiary.","length":405,"tagName":"p"},{"type":"text","content":"Over the past several weeks, multiple proprietary film platforms were evaluated at Vektor Pharma. One of these in-house platforms achieved highly promising results, generating first prototypes of Semaglutide-ODF formulations with strong performance characteristics. The prototypes demonstrated rapid disintegration, homogeneous film quality, good processability during manufacturing, and favorable mechanical properties. These results confirm the suitability of BioNxt's thin film technology for complex peptide formulations and provide a solid foundation for further development.","length":584,"tagName":"p"},{"type":"text","content":"This achievement marks a key advancement in the program and provides positive momentum as the project advances into its next stage.","length":131,"tagName":"p"},{"type":"text","content":""Achieving positive proof-of-concept results with first prototypes in-hand represents an important milestone for BioNxt," said Hugh Rogers, CEO of BioNxt Solutions. "These results validate our approach and allow us to proceed with greater confidence as we optimize the formulation, secure intellectual property, and prepare for preclinical testing."","length":369,"tagName":"p"},{"type":"text","content":"Patent Filing and Next-Stage Development","length":40,"tagName":"p"},{"type":"text","content":"Building on the successful prototypes, BioNxt is preparing to file a patent application for the Semaglutide ODF in the coming months. Under the supervision of Vektor Pharma, development will now transition toward refining the formulation to optimize performance and absorption potential, while also initiating stability studies, advancing scale-up work, and preparing the product for preclinical evaluation.","length":407,"tagName":"p"},{"type":"text","content":"These efforts are expected to continue through late 2025 and will culminate in a preclinical animal...